A role of myocardial stiffness in cell-based cardiac repair: a hypothesis

Shuning Zhang a, b, #, Aijun Sun a, b, #, Yanyan Liang a, Qinyi Chen a, Chunyu Zhang a, Keqiang Wang a, Yunzeng Zou a, b, *, Junbo Ge a, b, *

a Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China
b Institutes of Biomedical Sciences, Fudan University, Shanghai, China

Received: November 4, 2008; Accepted: January 19, 2009

Abstract

Determining which time point is optimal for bone marrow–derived cell (BMC) transplantation for acute myocardial infarction (AMI) has attracted a great deal of attention. Studies have verified the interaction between cell treatment effect and transfer timing and have suggested that the optimal time frame for BMC therapy is day 4 to day 7 after AMI. However, the potential mechanism underlying the time-dependent therapeutic response remains unclear. Recently, a growing body of in vitro evidence has suggested that stem cells are able to feel and respond to the stiffness of their microenvironment to commit to a relevant lineage, indicating that soft matrices that mimic brain are neurogenic, stiffer matrices that mimic muscle are myogenic and comparatively rigid matrices that mimic collagenous bone prove osteogenic. Simultaneously, considering the fact that the myocardium post-infarction experiences a time-dependent stiffness change from flexible to rigid as a result of myocardial remodelling following tissue necrosis and massive extracellular matrix deposition, we presume that the myocardial stiffness within a certain time frame (possibly day 4–7) post-AMI might provide a more favourable physical microenvironment for the phenotypic plasticity and functional specification of engrafted BMCs committed to some cell lineages, such as endothelial cells, vascular smooth muscle cells or cardiomyocytes. The beneficial effect facilitates angiogenesis and myocardigogenesis in the infarcted heart, and subsequently leads to more amelioration of cardiac functions. If the present hypothesis were true, it would be of great help to understand the mechanism underlying the optimal timing for BMC transplantation and to establish a direction for the time selection of cell therapy.

Keywords: stiffness • acute myocardial infarction • cell therapy • timing • hypothesis

The net loss of cardiomyocytes during myocardial infarction is a key factor in the resulting remodelling and in the impairment of cardiac-pump function [1]. Prompt reperfusion of the infarct-related coronary artery has considerably salvaged the ischaemic myocardium and limited the infarct size [2]. Nevertheless, heart failure that develops after infarction remains a leading cause of morbidity and mortality [3].

The bone marrow harbours stem cells and progenitor cells that may be capable of solid-organ repair [4]. Experimental studies have suggested that bone marrow–derived cell (BMC) transfer can enhance functional recovery after acute myocardial infarction (AMI) [5, 6]. Based on these data, stem cells and progenitor cells derived from bone marrow have been proposed for use in the repair of cardiac tissue after infarction in patients [7–9]. However, the reported benefits of cell therapy are very different among these studies. Of the various reasons for the different results, the timing of cell administration might be one of the most important factors affecting therapeutic efficacy. Recently this issue—what time point is optimal for the cell transplantation for AMI—has attracted a great deal of attention. An experimental study addressing the impacts of timing of transplantation on cardiac function post the infarction demonstrated that BMC therapy at 1 week after AMI was superior to transplantation within 1 hr and at 2 weeks [10]. Similarly, data from the largest randomized trial (REPAIR-AMI study [7]) of cell therapy for AMI to date verified the interaction between BMC treatment effect and transfer timing, indicating that BMC transfer on day 5 post-AMI or later resulted in a significant increase of left ventricular ejection fraction by 5.1%, whereas no benefit was observed in patients treated within day 4. The other
randomized controlled trial conducted by Janssens et al. [9] showed that cell transfer within 24 hrs post-AMI failed to improve left ventricular contractile function. Based on these preliminary results, the optimal time frame for cell therapy for AMI seems to be within the period from day 4 to day 7 after the infarction (Table 1).

However, the mechanism underlying time-dependent therapeutic efficacy remains unclear.

Current researches on this scientific issue tend to decipher it by time course of the production of inflammatory cytokines and growth factors after AMI, which were involved in survival and differentiation of the engrafted cells [6, 11, 12]. Experimentally, the early inflammatory process in infarcted myocardium, which might adversely affect the biological and functional behaviours of the engrafted cells, subsided at 1 week post-AMI [13], and meanwhile some beneficial factors (e.g. vascular endothelial growth factor [VEGF], hepatocyte growth factor [HGF]) are at their peak concentrations [14]. In this period, the biochemical microenvironment within the ischaemically injured myocardium might be suitable for the regeneration of functional myocardium and neovascularization in the broken heart associated with cell-replacement therapy [15–17]. However, it is noteworthy that the biochemical response within the myocardium after AMI is an exceedingly complex network. Although some inflammatory factors and cytokines may benefit the engrafted cells, the majority are believed to be deleterious for survival and differentiation of the stem cells [18]. Even the same cytokines often have

Table 1 Therapeutic efficacy and the time point of transplantation of bone marrow-derived cells

| Study | Publication | Sample size | Cell type injected | Time to cell transfer (days) | Follow-up (months) | Primary endpoints (control/treatment) |
|-------|-------------|-------------|--------------------|-----------------------------|-------------------|--------------------------------------|
| **Within 24 hrs after AMI** | | | | | | |
| Janssens S et al. [9] | Lancet 2006 | 67 | BMMNC | <1.0 | 4 | LVEF: Δ2.2%/Δ3.4%; P = 0.36 |
| **At day 4–7 after AMI** | | | | | | |
| REPAIR-AMI [7] | N Engl J Med 2006 | 204 | BMMNC | 4.3 | 4 | LVEF: Δ3.0%/Δ5.5%; P = 0.01 |
| BOOST [8] | Lancet 2004 | 65 | BMMNC | 4.8 | 6 | LVEF: Δ3.0%/Δ5.5%; P = 0.01 |
| Suarez de Lezo J et al. [26] | Rev Esp Cardiol 2007 | 20 | BMMNC | 7.0 | 3 | LVEF: Δ0.7%/Δ6.7%; P = 0.0026 |
| **More than 2 months after AMI** | | | | | | |
| Yao K et al. [27] | Heart 2008 | 47 | BMMNC | 390 | 6 | LVEF: Δ1.6%/Δ2.4%, P = 0.52; Infarct area: Δ-1.6%/Δ-2.3%, P = 0.35 |
| **Subgroup analysis in RCTs** | | | | | | |
| REPAIR-AMI7 | N Engl J Med 2006 | 204 | BMMNC | 4.3 | 4 | LVEF: Δ3.9%/Δ4.5%; P = 0.62 (within 4 days post-AMI); LVEF: Δ1.9%/Δ7.0%; P = 0.004 (at day 5–7 post-AMI) |
| | | | | | | P value for interaction = 0.03 |

| Study | Publication | Animal model | Cell type | Transfer timing | Follow-up (weeks) | Main results* |
|-------|-------------|--------------|-----------|----------------|------------------|---------------|
| Hu X et al. [10] | Eur J Cardiothorac Surg 2007 | SD rats | BMMSC | 1 hr, 1 week and 2 weeks | 2 | LVEF: 1 hr/1 week/2 weeks: 41.4%/48.1%/44.4%, P < 0.05; Infarct area: 1 hr/1 week/2 weeks: 41.4%/32.8%/37.1%, P < 0.05 |

*Comparison of each treatment group with the control group. Δ Changes from the baseline values.
AMI, acute myocardial infarction; BMMNC, bone marrow mononuclear cell; BMMSC, bone marrow mesenchymal stem cell; LVEF, left ventricular ejection fraction; RCTs, randomized controlled trials.
paradoxical effects or counteract each other [19, 20]. Obviously, it seems to be irrational to elucidate the mechanism of the time-dependent therapeutic effects of BMC delivery for AMI by several beneficial cytokines alone. On the basis of the data, there may exist other factors responsible for the fate of engrafted cells and subsequently impacting cell-based cardiac repair beyond the biochemical factors.

Recently, a growing body of evidence has also shown an effect of physical characteristics of the microenvironment around the engrafted cells on their differentiation, suggesting that the stiffness of matrix corresponding to specific tissues could promote tissue-mimetic differentiation of naive BMCs in vitro [21–23]. The cellular phenotype and behaviour post-differentiation induced by deformable matrix with varied stiffness may more closely mimic that of the cells in their normal host tissue. Concretely, soft matrices (elastic modulus \( E \), a material property that describes its stiffness or elasticity) of 0.1–1.0 kPa) that mimic brain favoured differentiation of BMCs into neuronal-like cells, moderate elasticity (\( E \sim 11 \) kPa) that mimics muscle-promoted myogenic differentiation, and a rigid matrix (\( E \sim 34 \) kPa) that mimics collagenous bone–stimulated osteogenic differentiation [21]. That is to say, stem cells are able to feel and respond to the stiffness of their microenvironment to commit to a relevant cell phenotype.

It is natural to associate these findings with the fact that the myocardium post-infarction experiences a time-dependent stiffness change from flexible to rigid. Pathologically and anatomically, the injured cardiomyocytes no longer stay intact in its early stage of infarction as tissue necrosis and inflammatory edema follow. Young scar formation begins about 1 week after the infarction. Scar maturation begins at 2 weeks and completes at 4 weeks after AMI [24]. The cardiac remodelling process following myocardial infarction is mainly induced by myocardial fibrosis starting with massive extracellular matrix deposition, which in combination with the tissue necrosis stiffens the heart muscle. Berry et al. experimentally found that the elastic modulus for the 2-week infarcted myocardium is threefold stiffer than the normal myocardium (\( E \sim 55 \) kPa) [25]. However, whether the time-related stiffness change in infarcted myocardium is associated with engrafted cells’ fate remains unclear.

Taken together, there exist three facts. First, the therapeutic effect of BMC transplantation for AMI is associated with the transfer timing. Second, the myocardium post-infarction experiences a time-dependent stiffness change. Third, matrix stiffness directs stem cell lineage specification. On the basis of these scientific findings, we presumed that myocardial stiffness within a certain time frame (possibly at day 4 to day 7) post-AMI might be more suitable for the phenotypic plasticity and functional specification of the engrafted BMC along some cell lineages, such as endothelial cells, smooth muscle cells or cardiomyocytes, than that at others time points, which facilitated angiogenesis and perhaps myocardiogenesis and, therefore, resulted in cardiac repair and amelioration of cardiac functions. The defined time domains will be regarded as the optimal time frame for the BMC administration for AMI.

To test our hypothesis, we performed preliminary in vitro experiments and observed that murine bone marrow mononuclear cells cultured in the medium with a matrix stiffness (\( E \sim 31 \) kPa) similar to the elasticity of infarcted myocardium at day 7 had a greater ability to differentiate into endothelial lineage cells, whereas those grown in the medium with a relatively soft matrix (\( E \sim 4–17 \) kPa) that mimics stiffness of infarcted myocardium between 1 hr and 24 hrs after AMI showed minimal differentiation.

If the present hypothesis is true, it will contribute greatly toward understanding the mechanism underlying the optimal timing for BMC transplantation and to establishing a direction for the time selection of cell therapy. Importantly, these patients with missed opportunity for cell transplantation will still be able to benefit from cell-replacement therapy by attenuating cardiac remodeling and consequently changing myocardial stiffness post the infarction. Cell transplantation in combination with anti-remodeling treatment might be more beneficial for patients on cardiac repair than the procedure used alone.

Acknowledgement

The study was supported by Shanghai Scientific Research Fund (06DJ14001), Program for Shanghai Outstanding Medical Academic Leader (LJ06008) and National Basic Research Program of China (2006CB943704).

References

1. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation. 1990; 81: 1161–72.

2. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003; 361: 13–20.

3. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM, Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003; 349: 1893–906.

4. Korbling M, Estrov Z. Adult stem cells for tissue repair — a new therapeutic concept? N Engl J Med. 2003; 349: 570–82.

5. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leri A, Anversa P. Bone marrow cells regenerate infarcted myocardium. Nature. 2001; 410: 701–5.

6. Kamihata H, Matsubara H, Nishiuie T, Fujiyama S, Tsutsumi Y, Ozono R, Masaki K, Leader (LJ06008) and National Basic Research Program of China (2006CB943704).
7. Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Hülschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Süselbeck T, Assmus B, Tonn T, Dimmeler S, Zeiher AM. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. *N Engl J Med.* 2006; 355: 1210–21.

8. Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breidenbach C, Fichtner S, Korte T, Hornig B, Messinger D, Arsenev L, Hertenstein B, Ganser A, Drexler H. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomized controlled clinical trial. *Lancet.* 2004; 364: 113–22.

9. Janssens S, Dubois C, Bogaert J, Theunissen K, Deroule C, Desmet W, Kalantzi M, Herbots L, Simaeev P, Dens J, Maertens J, Rademakers F, Dymarkowski S, Gheyssens O, Van Cleemput J, Bormans G, Nuyts J, Delmansi A, Mortelmans L, Boogaerts M, Van de Werf F. Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety. *Circulation.* 2005; 112: 1178–83.

10. Deten A, Volz HC, Brist W, Zimmer HG. Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats. *Cardiovasc. Res.* 2002; 55: 329–40.

11. Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K, Fukuda N. Serial changes in serum VEGF and HGF in patients with acute myocardial infarction. *Cardiology.* 2000; 93: 168–74.

12. Matsumoto R, Omura T, Yoshiyama M, Hayashi T, Inamoto S, Koh KR, Ohta K, Izumi Y, Nakamura Y, Akioka K, Kitaura Y, Takeuchi K, Yoshikawa J. Vascular endothelial growth factor-expressing mesenchymal stem cell transplantation for the treatment of acute myocardial infarction. *Arterioscler. Thromb. Vasc. Biol.* 2005; 25: 1168–73.

13. Granata R, Trovato L, Lupia E, Sala G, Sattanni F, Camussi G, Ghidoni R, Ghigo E. Insulin-like growth factor binding protein-3 induces angiogenesis through IGF-I-dependent mechanisms. *Thromb. Haemost.* 2007; 5: 835–45.

14. Maulik N, Thirunavukkarasu M. Growth factors and cell therapy in myocardial regeneration. *J Mol Cell Cardiol.* 2008; 44: 219–27.

15. Fibbe WE, Pruijt JF, van Kooyk Y, Figdor CG, Opdenakker G, Willemsen R. The role of metalloproteinases and adhesion molecules in interleukin-8-induced stem-cell mobilization. *Semin. Hematol.* 2000; 37: 19–24.

16. Nian M, Lee P, Khaeder N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. *Circ. Res.* 2004; 94: 1543–53.

17. Vanderweide S, van Luyn MJ, Tio RA, Harmsen MC. Signaling factors in stem cell-mediated repair of infarcted myocardium. *J Mol Cell Cardiol.* 2005; 39: 363–76.

18. Engler AJ, Sen S, Sweeney HL, Discher DE. Matrix elasticity directs stem cell lineage specification. *Cell.* 2006; 126: 677–89.

19. Discher DE, Janmey P, Wang YL. Tissue cells feel and respond to the stiffness of their substrate. *Science.* 2005; 310: 1139–43.

20. Engler AJ, Griffin MA, Sen S, Bönnemann CG, Sweeney HL, Discher DE. Myotubes differentiate optimally on substrates with tissue-like stiffness: pathological implications for soft or stiff microenvironments. *J Cell Biol.* 2004; 166: 877–87.

21. Virag JI, Murry CE. Myofibroblast and endothelial cell proliferation during murine myocardial infarct repair. *Am J Pathol.* 2003; 163: 2433–40.

22. Berry MF, Engler AJ, Woo YJ, Pirolli TJ, Bish LT, Jayasankar V, Morine KJ, Gardner TJ, Discher DE, Sweeney HL. Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance. *Am J Physiol. Heart Circ. Physiol.* 2006; 290: H2196–203.

23. Sánchez J, Ojeda S, Pan M, Romero M, Pavlovic D, Segura J, Sánchez J, Ojeda S, Torres A. Regenerative therapy in patients with a recanalized acute anterior myocardial infarction and depressed ventricular function. *Rev Esp. Cardiol.* 2007; 60: 357–65.

24. Yao K, Huang R, Qian J, Cui J, Ge L, Li Y, Zhang F, Shi H, Huang D, Zhang S, Sun A, Zou Y, Ge J. Administration of intracoronary bone marrow mononuclear cells on chronic myocardial infarction improves diastolic function. *Heart.* 2008; 94: 1147–53.